A recently-approved treatment could take a BiTE out of small cell lung cancer by using a person's own body to fight back.

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

Merck (MRK) stock falls as the company withdraws U.S. marketing application for lung cancer therapy HER3-DXd developed with ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

In this Review, Simpson et al. summarize the emergent understanding of molecular subtypes of small cell lung cancer (SCLC). They discuss how intratumour heterogeneity and dynamic tumour plasticity ...

Summit Therapeutics (NASDAQ:SMMT) announced on Friday that its lead asset, ivonescimab, developed with its Chinese partner ...

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA ... patients with previous or current evidence of interstitial lung disease (ILD) were excluded. An Eastern ...

Daiichi Sankyo and MSD have voluntarily withdrawn the biologics licence application (BLA) in the US for their HER3-directed DXd antibody drug conjugate (ADC) patritumab deruxtecan, intended for ...